Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Entasis Therapeutics Holdings Inc. ETTX
$2.19
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
-
week52low
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.32633000
-
EPS
-1.12300000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 авг 2022 г. в 04:00
Описание компании
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Cantor Fitzgerald | Neutral | Overweight | 06 мая 2022 г. |
Alliance Global Partners | Neutral | Buy | 16 мар 2022 г. |
Wedbush | Neutral | Outperform | 08 мар 2022 г. |
HC Wainwright & Co. | Neutral | Buy | 04 мар 2022 г. |
BMO Capital | Outperform | Outperform | 20 окт 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Insider Summary
Insider Summary
Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
---|---|---|---|---|
Innoviva, Inc. | A | 29270476 | 7598814 | 11 июл 2022 г. |
Triola Anna Diaz | D | 0 | 100000 | 11 июл 2022 г. |
Triola Anna Diaz | D | 0 | 125000 | 11 июл 2022 г. |
Wagner Kristie Ann | D | 0 | 73400 | 11 июл 2022 г. |
Wagner Kristie Ann | D | 0 | 80500 | 11 июл 2022 г. |
Ronsheim Matthew | D | 0 | 20000 | 11 июл 2022 г. |
Ronsheim Matthew | D | 0 | 150000 | 11 июл 2022 г. |
Tommasi Ruben | D | 0 | 6465 | 11 июл 2022 г. |
Tommasi Ruben | D | 0 | 150000 | 11 июл 2022 г. |
Mueller John Patrick | D | 0 | 18253 | 11 июл 2022 г. |
Свежие комментарии
Свежие комментарии